Shows
CME/CEEmerging data with potentially guideline-changing implications in CLL/SLL and MCL
Host: Seema A. Bhat, MD
Host: Jeremy S. Abramson, MD, MMSc
This enduring activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating CLL/SLL and MCL. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans for patients that have progressed following a covalent BTK inhibitor. The program highlights the importance of evidence-based approaches and the use of noncovalent BTK inhibitors for relapsed/refractory CLL/SLL and MCL. Attendees will also explore emerging data that could influence future treatment guidelines, a...2025-01-2300 minCME/CEGuideline-recommended treatment options for patients with CLL/SLL and MCL that have progressed following a covalent BTK inhibitor
Host: Seema A. Bhat, MD
Host: Jeremy S. Abramson, MD, MMSc
This enduring activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating CLL/SLL and MCL. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans for patients that have progressed following a covalent BTK inhibitor. The program highlights the importance of evidence-based approaches and the use of noncovalent BTK inhibitors for relapsed/refractory CLL/SLL and MCL. Attendees will also explore emerging data that could influence future treatment guidelines, a...2025-01-2300 minCME/CEIncorporating guideline-concordant care for patients with CLL/SLL relapsing after 2 prior lines of therapy
Host: Seema A. Bhat, MD
Host: Jeremy S. Abramson, MD, MMSc
This enduring activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating CLL/SLL and MCL. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans for patients that have progressed following a covalent BTK inhibitor. The program highlights the importance of evidence-based approaches and the use of noncovalent BTK inhibitors for relapsed/refractory CLL/SLL and MCL. Attendees will also explore emerging data that could influence future treatment guidelines, a...2025-01-2300 minCME/CEClinical trial evidence that drives current guidelines for patients with CLL/SLL and MCL receiving third-line therapies
Host: Seema A. Bhat, MD
Host: Jeremy S. Abramson, MD, MMSc
This enduring activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating CLL/SLL and MCL. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans for patients that have progressed following a covalent BTK inhibitor. The program highlights the importance of evidence-based approaches and the use of noncovalent BTK inhibitors for relapsed/refractory CLL/SLL and MCL. Attendees will also explore emerging data that could influence future treatment guidelines, a...2025-01-2300 minReachMD CMEGuideline-recommended treatment options for patients with CLL/SLL and MCL that have progressed following a covalent BTK inhibitorCME credits: 0.50
Valid until: 23-01-2026
Claim your CME credit at https://reachmd.com/programs/cme/guideline-recommended-treatment-options-for-patients-with-cllsll-and-mcl-that-have-progressed-following-a-covalent-btk-inhibitor/32284/
This enduring activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating CLL/SLL and MCL. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans for patients that have progressed following a covalent BTK inhibitor. The program highlights the importance of evidence-based approaches and the use of noncovalent BTK inhibitors for relapsed/refractory CLL/SLL and MCL. Attendees will also explore emerging d...2025-01-2300 minReachMD CMEClinical trial evidence that drives current guidelines for patients with CLL/SLL and MCL receiving third-line therapiesCME credits: 0.50
Valid until: 23-01-2026
Claim your CME credit at https://reachmd.com/programs/cme/clinical-trial-evidence-that-drives-current-guidelines-for-patients-with-cllsll-and-mcl-receiving-third-line-therapies/32285/
This enduring activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating CLL/SLL and MCL. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans for patients that have progressed following a covalent BTK inhibitor. The program highlights the importance of evidence-based approaches and the use of noncovalent BTK inhibitors for relapsed/refractory CLL/SLL and MCL. Attendees will also explore emerging d...2025-01-2300 minReachMD CMEIncorporating guideline-concordant care for patients with CLL/SLL relapsing after 2 prior lines of therapyCME credits: 0.50
Valid until: 23-01-2026
Claim your CME credit at https://reachmd.com/programs/cme/incorporating-guideline-concordant-care-for-patients-with-cllsll-relapsing-after-2-prior-lines-of-therapy/32286/
This enduring activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating CLL/SLL and MCL. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans for patients that have progressed following a covalent BTK inhibitor. The program highlights the importance of evidence-based approaches and the use of noncovalent BTK inhibitors for relapsed/refractory CLL/SLL and MCL. Attendees will also explore e...2025-01-2300 minReachMD CMEEmerging data with potentially guideline-changing implications in CLL/SLL and MCLCME credits: 0.50
Valid until: 23-01-2026
Claim your CME credit at https://reachmd.com/programs/cme/emerging-data-with-potentially-guideline-changing-implications-in-cllsll-and-mcl/32287/
This enduring activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating CLL/SLL and MCL. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans for patients that have progressed following a covalent BTK inhibitor. The program highlights the importance of evidence-based approaches and the use of noncovalent BTK inhibitors for relapsed/refractory CLL/SLL and MCL. Attendees will also explore emerging d...2025-01-2300 minCMEEmerging data with potentially guideline-changing implications in CLL/SLL and MCL
Host: Seema A. Bhat, MD
Host: Jeremy S. Abramson, MD, MMSc
This enduring activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating CLL/SLL and MCL. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans for patients that have progressed following a covalent BTK inhibitor. The program highlights the importance of evidence-based approaches and the use of noncovalent BTK inhibitors for relapsed/refractory CLL/SLL and MCL. Attendees will also explore emerging data that could influence future treatment guidelines, a...2025-01-2300 minReachMD CMEGuideline-recommended treatment options for patients with CLL/SLL and MCL that have progressed following a covalent BTK inhibitorCME credits: 0.50
Valid until: 23-01-2026
Claim your CME credit at https://reachmd.com/programs/cme/guideline-recommended-treatment-options-for-patients-with-cllsll-and-mcl-that-have-progressed-following-a-covalent-btk-inhibitor/32284/
This enduring activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating CLL/SLL and MCL. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans for patients that have progressed following a covalent BTK inhibitor. The program highlights the importance of evidence-based approaches and the use of noncovalent BTK inhibitors for relapsed/refractory CLL/SLL and MCL. Attendees will also explore emerging d...2025-01-2300 minReachMD CMEClinical trial evidence that drives current guidelines for patients with CLL/SLL and MCL receiving third-line therapiesCME credits: 0.50
Valid until: 23-01-2026
Claim your CME credit at https://reachmd.com/programs/cme/clinical-trial-evidence-that-drives-current-guidelines-for-patients-with-cllsll-and-mcl-receiving-third-line-therapies/32285/
This enduring activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating CLL/SLL and MCL. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans for patients that have progressed following a covalent BTK inhibitor. The program highlights the importance of evidence-based approaches and the use of noncovalent BTK inhibitors for relapsed/refractory CLL/SLL and MCL. Attendees will also explore emerging d...2025-01-2300 minReachMD CMEIncorporating guideline-concordant care for patients with CLL/SLL relapsing after 2 prior lines of therapyCME credits: 0.50
Valid until: 23-01-2026
Claim your CME credit at https://reachmd.com/programs/cme/incorporating-guideline-concordant-care-for-patients-with-cllsll-relapsing-after-2-prior-lines-of-therapy/32286/
This enduring activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating CLL/SLL and MCL. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans for patients that have progressed following a covalent BTK inhibitor. The program highlights the importance of evidence-based approaches and the use of noncovalent BTK inhibitors for relapsed/refractory CLL/SLL and MCL. Attendees will also explore e...2025-01-2300 minReachMD CMEEmerging data with potentially guideline-changing implications in CLL/SLL and MCLCME credits: 0.50
Valid until: 23-01-2026
Claim your CME credit at https://reachmd.com/programs/cme/emerging-data-with-potentially-guideline-changing-implications-in-cllsll-and-mcl/32287/
This enduring activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating CLL/SLL and MCL. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans for patients that have progressed following a covalent BTK inhibitor. The program highlights the importance of evidence-based approaches and the use of noncovalent BTK inhibitors for relapsed/refractory CLL/SLL and MCL. Attendees will also explore emerging d...2025-01-2300 minCMEIncorporating guideline-concordant care for patients with CLL/SLL relapsing after 2 prior lines of therapy
Host: Seema A. Bhat, MD
Host: Jeremy S. Abramson, MD, MMSc
This enduring activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating CLL/SLL and MCL. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans for patients that have progressed following a covalent BTK inhibitor. The program highlights the importance of evidence-based approaches and the use of noncovalent BTK inhibitors for relapsed/refractory CLL/SLL and MCL. Attendees will also explore emerging data that could influence future treatment guidelines, a...2025-01-2300 minCMEGuideline-recommended treatment options for patients with CLL/SLL and MCL that have progressed following a covalent BTK inhibitor
Host: Seema A. Bhat, MD
Host: Jeremy S. Abramson, MD, MMSc
This enduring activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating CLL/SLL and MCL. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans for patients that have progressed following a covalent BTK inhibitor. The program highlights the importance of evidence-based approaches and the use of noncovalent BTK inhibitors for relapsed/refractory CLL/SLL and MCL. Attendees will also explore emerging data that could influence future treatment guidelines, a...2025-01-2300 minCMEClinical trial evidence that drives current guidelines for patients with CLL/SLL and MCL receiving third-line therapies
Host: Seema A. Bhat, MD
Host: Jeremy S. Abramson, MD, MMSc
This enduring activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating CLL/SLL and MCL. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans for patients that have progressed following a covalent BTK inhibitor. The program highlights the importance of evidence-based approaches and the use of noncovalent BTK inhibitors for relapsed/refractory CLL/SLL and MCL. Attendees will also explore emerging data that could influence future treatment guidelines, a...2025-01-2300 minCMEEmerging data with potentially guideline-changing implications in CLL/SLL and MCL
Host: Seema A. Bhat, MD
Host: Jeremy S. Abramson, MD, MMSc
This enduring activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating CLL/SLL and MCL. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans for patients that have progressed following a covalent BTK inhibitor. The program highlights the importance of evidence-based approaches and the use of noncovalent BTK inhibitors for relapsed/refractory CLL/SLL and MCL. Attendees will also explore emerging data that could influence future treatment guidelines, a...2025-01-2300 minCMEIncorporating guideline-concordant care for patients with CLL/SLL relapsing after 2 prior lines of therapy
Host: Seema A. Bhat, MD
Host: Jeremy S. Abramson, MD, MMSc
This enduring activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating CLL/SLL and MCL. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans for patients that have progressed following a covalent BTK inhibitor. The program highlights the importance of evidence-based approaches and the use of noncovalent BTK inhibitors for relapsed/refractory CLL/SLL and MCL. Attendees will also explore emerging data that could influence future treatment guidelines, a...2025-01-2300 minCMEClinical trial evidence that drives current guidelines for patients with CLL/SLL and MCL receiving third-line therapies
Host: Seema A. Bhat, MD
Host: Jeremy S. Abramson, MD, MMSc
This enduring activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating CLL/SLL and MCL. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans for patients that have progressed following a covalent BTK inhibitor. The program highlights the importance of evidence-based approaches and the use of noncovalent BTK inhibitors for relapsed/refractory CLL/SLL and MCL. Attendees will also explore emerging data that could influence future treatment guidelines, a...2025-01-2300 minCMEGuideline-recommended treatment options for patients with CLL/SLL and MCL that have progressed following a covalent BTK inhibitor
Host: Seema A. Bhat, MD
Host: Jeremy S. Abramson, MD, MMSc
This enduring activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating CLL/SLL and MCL. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans for patients that have progressed following a covalent BTK inhibitor. The program highlights the importance of evidence-based approaches and the use of noncovalent BTK inhibitors for relapsed/refractory CLL/SLL and MCL. Attendees will also explore emerging data that could influence future treatment guidelines, a...2025-01-2300 minCME/CEEmerging data with potentially guideline-changing implications in CLL/SLL and MCL
Host: Seema A. Bhat, MD
Host: Jeremy S. Abramson, MD, MMSc
This enduring activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating CLL/SLL and MCL. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans for patients that have progressed following a covalent BTK inhibitor. The program highlights the importance of evidence-based approaches and the use of noncovalent BTK inhibitors for relapsed/refractory CLL/SLL and MCL. Attendees will also explore emerging data that could influence future treatment guidelines, a...2025-01-2300 minCME/CEIncorporating guideline-concordant care for patients with CLL/SLL relapsing after 2 prior lines of therapy
Host: Seema A. Bhat, MD
Host: Jeremy S. Abramson, MD, MMSc
This enduring activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating CLL/SLL and MCL. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans for patients that have progressed following a covalent BTK inhibitor. The program highlights the importance of evidence-based approaches and the use of noncovalent BTK inhibitors for relapsed/refractory CLL/SLL and MCL. Attendees will also explore emerging data that could influence future treatment guidelines, a...2025-01-2300 minCME/CEClinical trial evidence that drives current guidelines for patients with CLL/SLL and MCL receiving third-line therapies
Host: Seema A. Bhat, MD
Host: Jeremy S. Abramson, MD, MMSc
This enduring activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating CLL/SLL and MCL. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans for patients that have progressed following a covalent BTK inhibitor. The program highlights the importance of evidence-based approaches and the use of noncovalent BTK inhibitors for relapsed/refractory CLL/SLL and MCL. Attendees will also explore emerging data that could influence future treatment guidelines, a...2025-01-2300 minCME/CEGuideline-recommended treatment options for patients with CLL/SLL and MCL that have progressed following a covalent BTK inhibitor
Host: Seema A. Bhat, MD
Host: Jeremy S. Abramson, MD, MMSc
This enduring activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating CLL/SLL and MCL. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans for patients that have progressed following a covalent BTK inhibitor. The program highlights the importance of evidence-based approaches and the use of noncovalent BTK inhibitors for relapsed/refractory CLL/SLL and MCL. Attendees will also explore emerging data that could influence future treatment guidelines, a...2025-01-2300 minCMEChairperson Perspective: Practice-Changing Strategies in Community Care Settings for Patients with CLL/SLL and MCL
Host: Matthew S. Davids, MD, MMSc
Although covalent Bruton's tyrosine kinase (BTK) inhibitors have proven to be effective in treating chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) or mantle cell lymphoma (MCL), patients still experience poor outcomes after treatment failure or intolerance, necessitating new therapeutic options. Next-generation non-covalent, reversible BTK inhibitors, which have increased specificity and a novel mechanism of action, may address unmet needs and deliver better care. These next-generation BTK inhibitors have been successful in clinical trials and are changing the treatment paradigm as well as practice guidelines. Understanding key differences between the covalent and...2024-07-2300 minCME/CEChairperson Perspective: Practice-Changing Strategies in Community Care Settings for Patients with CLL/SLL and MCL
Host: Matthew S. Davids, MD, MMSc
Although covalent Bruton's tyrosine kinase (BTK) inhibitors have proven to be effective in treating chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) or mantle cell lymphoma (MCL), patients still experience poor outcomes after treatment failure or intolerance, necessitating new therapeutic options. Next-generation non-covalent, reversible BTK inhibitors, which have increased specificity and a novel mechanism of action, may address unmet needs and deliver better care. These next-generation BTK inhibitors have been successful in clinical trials and are changing the treatment paradigm as well as practice guidelines. Understanding key differences between the covalent and...2024-07-2300 minCME/CEChairperson Perspective: Practice-Changing Strategies in Community Care Settings for Patients with CLL/SLL and MCL
Host: Matthew S. Davids, MD, MMSc
Although covalent Bruton's tyrosine kinase (BTK) inhibitors have proven to be effective in treating chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) or mantle cell lymphoma (MCL), patients still experience poor outcomes after treatment failure or intolerance, necessitating new therapeutic options. Next-generation non-covalent, reversible BTK inhibitors, which have increased specificity and a novel mechanism of action, may address unmet needs and deliver better care. These next-generation BTK inhibitors have been successful in clinical trials and are changing the treatment paradigm as well as practice guidelines. Understanding key differences between the covalent and...2024-07-2300 minCMEChairperson Perspective: Practice-Changing Strategies in Community Care Settings for Patients with CLL/SLL and MCL
Host: Matthew S. Davids, MD, MMSc
Although covalent Bruton's tyrosine kinase (BTK) inhibitors have proven to be effective in treating chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) or mantle cell lymphoma (MCL), patients still experience poor outcomes after treatment failure or intolerance, necessitating new therapeutic options. Next-generation non-covalent, reversible BTK inhibitors, which have increased specificity and a novel mechanism of action, may address unmet needs and deliver better care. These next-generation BTK inhibitors have been successful in clinical trials and are changing the treatment paradigm as well as practice guidelines. Understanding key differences between the covalent and...2024-07-2300 minReachMD CMEChairperson Perspective: Practice-Changing Strategies in Community Care Settings for Patients with CLL/SLL and MCLCME credits: 0.50
Valid until: 23-07-2025
Claim your CME credit at https://reachmd.com/programs/cme/chairperson-perspective-practice-changing-strategies-in-community-care-settings-for-patients-with-cllsll-and-mcl/18098/
Although covalent Bruton's tyrosine kinase (BTK) inhibitors have proven to be effective in treating chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) or mantle cell lymphoma (MCL), patients still experience poor outcomes after treatment failure or intolerance, necessitating new therapeutic options. Next-generation non-covalent, reversible BTK inhibitors, which have increased specificity and a novel mechanism of action, may address unmet needs and deliver better care. These next-generation BTK inhibitors have been successful in clinical trials and are changing the treatment...2024-07-2300 minReachMD CMEChairperson Perspective: Practice-Changing Strategies in Community Care Settings for Patients with CLL/SLL and MCLCME credits: 0.50
Valid until: 23-07-2025
Claim your CME credit at https://reachmd.com/programs/cme/chairperson-perspective-practice-changing-strategies-in-community-care-settings-for-patients-with-cllsll-and-mcl/18098/
Although covalent Bruton's tyrosine kinase (BTK) inhibitors have proven to be effective in treating chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) or mantle cell lymphoma (MCL), patients still experience poor outcomes after treatment failure or intolerance, necessitating new therapeutic options. Next-generation non-covalent, reversible BTK inhibitors, which have increased specificity and a novel mechanism of action, may address unmet needs and deliver better care. These next-generation BTK inhibitors have been successful in clinical trials and are changing the treatment...2024-07-2300 min
CCO Oncology PodcastCurrent Clinical Practice and NCCN Guidelines for CLL/SLLIn this podcast episode, Farrukh Awan, MD, Jeremy S. Abramson, MD, MMSc, and Shuo Ma, MD, PhD, discuss real-world patient cases and how to align current clinical practice with the NCCN guidelines for CLL/SLL, including:Prognostic variables when deciding between regimensRole of MRD in CLLResults from the phase II CAPTIVATE trialChoosing among the available covalent BTK inhibitorsPreferred partner anti-CD20 antibody in CLL/SLLRole of the noncovalent BTK inhibitor, pirtobrutinib, in CLL/SLLUse of CAR T-cell therapy in CLL/SLLPresenters:Farrukh Awan, MDProfessor of Internal MedicineDirector of Lymphoid Malignancies P...2024-07-1831 min
The Fellow on Call: The Heme/Onc PodcastEpisode 095: Introduction to CLL/SLLThis week, we start a new series, this time all about the ins-and-outs of chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma (SLL)! Whether practicing general internal medicine, hospital medicine, or hematology/oncology, you will likely come across a patient with CLL. First, we go through initial diagnosis of this disease! Content: - What is CLL? How is this different than SLL?- What is the approach to diagnosis?- Do you need a bone marrow biopsy? Imaging?- How do we prognosticate patients? - Are smudge cells...2024-03-0600 min
OncLive® On AirFDA Approval Insights: Pirtobrutunib in Previously Treated CLL/SLLDr Davids discusses the FDA approval of pirtobrutinib for patients with previously treated CLL/SLL; key efficacy and safety data from the BRUIN trial; and guidelines for pirtobrutinib use in clinical practice in the CLL/SLL patient population.2024-01-2510 min
Oncology Data AdvisorPatterns of Care With BTK Inhibitors for CLL/SLL in the Community Setting: David Andorsky, MDAt the recent American Society of Hematology (ASH) Annual Meeting in San Diego, Dr. David Andorsky, MD, a Clinical Hematologist and Medical Oncologist at the Rocky Mountain Cancer Centers in Boulder, Colorado, presented his research and observations regarding patterns of care with Bruton tyrosine kinase (BTK) inhibitors and the distribution of social determinants of health among patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL). In this interview, he further discusses how the treatment landscape of CLL/SLL has changed with the introduction of BTK inhibitors and his next steps for this research.2024-01-1806 min
CME in Minutes: Education in Primary CareTanya Siddiqi, MD - Addressing Patient Needs With CAR T-Cell Therapy in the Treatment of CLL/SLL: Preparing for an Evolving Treatment ParadigmPlease visit answersincme.com/DTC860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in hematologic cancers discusses management of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma and the future use of CAR T-cell therapies. Upon completion of this activity, participants should be better able to: Identify the unmet therapeutic needs in the management of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL); Describe the clinical evidence of novel and emerging therapies being investigated to address unmet therapeutic needs in the management of CLL/SLL; and Outline...2024-01-0413 min
CME in Minutes: Education in Oncology & HematologyTanya Siddiqi, MD - Addressing Patient Needs With CAR T-Cell Therapy in the Treatment of CLL/SLL: Preparing for an Evolving Treatment ParadigmPlease visit answersincme.com/DTC860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in hematologic cancers discusses management of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma and the future use of CAR T-cell therapies. Upon completion of this activity, participants should be better able to: Identify the unmet therapeutic needs in the management of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL); Describe the clinical evidence of novel and emerging therapies being investigated to address unmet therapeutic needs in the management of CLL/SLL; and Outline...2024-01-0413 minCME in Minutes: Education in Oncology & HematologyMiguel-Angel Perales, MD - Shifting Gears in Treating Relapsed and Refractory Indolent B-Cell Lymphomas: Where Do CAR T Cell Therapies Stand in FL and CLL/SLL?Please visit answersincme.com/FSV860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in hematologic cancer discusses the use of chimeric antigen receptor (CAR) T cell therapies in B-cell lymphoma. Upon completion of this activity, participants should be better able to: Recognize the clinical rationale for using chimeric antigen receptor (CAR) T cell therapies for relapsed/refractory indolent follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL); Describe the clinical profiles of approved and emerging CD19-directed CAR T cell therapies for relapsed/refractory indolent FL...2023-07-0413 minCME in Minutes: Education in Primary CareMiguel-Angel Perales, MD - Shifting Gears in Treating Relapsed and Refractory Indolent B-Cell Lymphomas: Where Do CAR T Cell Therapies Stand in FL and CLL/SLL?Please visit answersincme.com/FSV860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in hematologic cancer discusses the use of chimeric antigen receptor (CAR) T cell therapies in B-cell lymphoma. Upon completion of this activity, participants should be better able to: Recognize the clinical rationale for using chimeric antigen receptor (CAR) T cell therapies for relapsed/refractory indolent follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL); Describe the clinical profiles of approved and emerging CD19-directed CAR T cell therapies for relapsed/refractory indolent FL...2023-07-0413 min
PeerView Immunology & Transplantation CME/CNE/CPE Video PodcastDr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD / Anthony R. Mato, MD, MSCE - Upgrading the Sequential Therapy Tool Kit for B-Cell Malignancies: New Evidence on the Individualized Use of BTK Inhibitors in Relapsed/Refractory CLL/SLL and MCLGo online to PeerView.com/DQM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up to the challenge of selecting and sequencing BTK inhibitor options in difficult B-cell cancer settings? This PeerView MasterClass and Case Forum activity recorded at the European hematology annual meeting explores BTK inhibitors as highly effective therapeutic tools for treating R/R CLL/SLL and MCL; join the experts and learn about important evidence on the “upgraded” sequential use of BTK inhibitors and other therapeutic innovations in pretreated B-cell cancer settings. Throughout, the experts will provide case...2022-08-101h 09
PeerView Heart, Lung & Blood CME/CNE/CPE Video PodcastDr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD / Anthony R. Mato, MD, MSCE - Upgrading the Sequential Therapy Tool Kit for B-Cell Malignancies: New Evidence on the Individualized Use of BTK Inhibitors in Relapsed/Refractory CLL/SLL and MCLGo online to PeerView.com/DQM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up to the challenge of selecting and sequencing BTK inhibitor options in difficult B-cell cancer settings? This PeerView MasterClass and Case Forum activity recorded at the European hematology annual meeting explores BTK inhibitors as highly effective therapeutic tools for treating R/R CLL/SLL and MCL; join the experts and learn about important evidence on the “upgraded” sequential use of BTK inhibitors and other therapeutic innovations in pretreated B-cell cancer settings. Throughout, the experts will provide case...2022-08-101h 09
PeerView Oncology & Hematology CME/CNE/CPE Video PodcastDr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD / Anthony R. Mato, MD, MSCE - Upgrading the Sequential Therapy Tool Kit for B-Cell Malignancies: New Evidence on the Individualized Use of BTK Inhibitors in Relapsed/Refractory CLL/SLL and MCLGo online to PeerView.com/DQM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up to the challenge of selecting and sequencing BTK inhibitor options in difficult B-cell cancer settings? This PeerView MasterClass and Case Forum activity recorded at the European hematology annual meeting explores BTK inhibitors as highly effective therapeutic tools for treating R/R CLL/SLL and MCL; join the experts and learn about important evidence on the “upgraded” sequential use of BTK inhibitors and other therapeutic innovations in pretreated B-cell cancer settings. Throughout, the experts will provide case...2022-08-101h 09
PeerView Clinical Pharmacology CME/CNE/CPE VideoDr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD / Anthony R. Mato, MD, MSCE - Upgrading the Sequential Therapy Tool Kit for B-Cell Malignancies: New Evidence on the Individualized Use of BTK Inhibitors in Relapsed/Refractory CLL/SLL and MCLGo online to PeerView.com/DQM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up to the challenge of selecting and sequencing BTK inhibitor options in difficult B-cell cancer settings? This PeerView MasterClass and Case Forum activity recorded at the European hematology annual meeting explores BTK inhibitors as highly effective therapeutic tools for treating R/R CLL/SLL and MCL; join the experts and learn about important evidence on the “upgraded” sequential use of BTK inhibitors and other therapeutic innovations in pretreated B-cell cancer settings. Throughout, the experts will provide case...2022-08-101h 09
PeerView Heart, Lung & Blood CME/CNE/CPE Audio PodcastDr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD / Anthony R. Mato, MD, MSCE - Upgrading the Sequential Therapy Tool Kit for B-Cell Malignancies: New Evidence on the Individualized Use of BTK Inhibitors in Relapsed/Refractory CLL/SLL and MCLGo online to PeerView.com/DQM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up to the challenge of selecting and sequencing BTK inhibitor options in difficult B-cell cancer settings? This PeerView MasterClass and Case Forum activity recorded at the European hematology annual meeting explores BTK inhibitors as highly effective therapeutic tools for treating R/R CLL/SLL and MCL; join the experts and learn about important evidence on the “upgraded” sequential use of BTK inhibitors and other therapeutic innovations in pretreated B-cell cancer settings. Throughout, the experts will provide case...2022-08-101h 09
PeerView Internal Medicine CME/CNE/CPE Audio PodcastDr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD / Anthony R. Mato, MD, MSCE - Upgrading the Sequential Therapy Tool Kit for B-Cell Malignancies: New Evidence on the Individualized Use of BTK Inhibitors in Relapsed/Refractory CLL/SLL and MCLGo online to PeerView.com/DQM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up to the challenge of selecting and sequencing BTK inhibitor options in difficult B-cell cancer settings? This PeerView MasterClass and Case Forum activity recorded at the European hematology annual meeting explores BTK inhibitors as highly effective therapeutic tools for treating R/R CLL/SLL and MCL; join the experts and learn about important evidence on the “upgraded” sequential use of BTK inhibitors and other therapeutic innovations in pretreated B-cell cancer settings. Throughout, the experts will provide case...2022-08-101h 09
PeerView Oncology & Hematology CME/CNE/CPE Audio PodcastDr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD / Anthony R. Mato, MD, MSCE - Upgrading the Sequential Therapy Tool Kit for B-Cell Malignancies: New Evidence on the Individualized Use of BTK Inhibitors in Relapsed/Refractory CLL/SLL and MCLGo online to PeerView.com/DQM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up to the challenge of selecting and sequencing BTK inhibitor options in difficult B-cell cancer settings? This PeerView MasterClass and Case Forum activity recorded at the European hematology annual meeting explores BTK inhibitors as highly effective therapeutic tools for treating R/R CLL/SLL and MCL; join the experts and learn about important evidence on the “upgraded” sequential use of BTK inhibitors and other therapeutic innovations in pretreated B-cell cancer settings. Throughout, the experts will provide case...2022-08-101h 09
PeerView Clinical Pharmacology CME/CNE/CPE Audio PodcastDr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD / Anthony R. Mato, MD, MSCE - Upgrading the Sequential Therapy Tool Kit for B-Cell Malignancies: New Evidence on the Individualized Use of BTK Inhibitors in Relapsed/Refractory CLL/SLL and MCLGo online to PeerView.com/DQM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up to the challenge of selecting and sequencing BTK inhibitor options in difficult B-cell cancer settings? This PeerView MasterClass and Case Forum activity recorded at the European hematology annual meeting explores BTK inhibitors as highly effective therapeutic tools for treating R/R CLL/SLL and MCL; join the experts and learn about important evidence on the “upgraded” sequential use of BTK inhibitors and other therapeutic innovations in pretreated B-cell cancer settings. Throughout, the experts will provide case...2022-08-101h 09
PeerView Internal Medicine CME/CNE/CPE Video PodcastDr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD / Anthony R. Mato, MD, MSCE - Upgrading the Sequential Therapy Tool Kit for B-Cell Malignancies: New Evidence on the Individualized Use of BTK Inhibitors in Relapsed/Refractory CLL/SLL and MCLGo online to PeerView.com/DQM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up to the challenge of selecting and sequencing BTK inhibitor options in difficult B-cell cancer settings? This PeerView MasterClass and Case Forum activity recorded at the European hematology annual meeting explores BTK inhibitors as highly effective therapeutic tools for treating R/R CLL/SLL and MCL; join the experts and learn about important evidence on the “upgraded” sequential use of BTK inhibitors and other therapeutic innovations in pretreated B-cell cancer settings. Throughout, the experts will provide case...2022-08-101h 09
PeerView Immunology & Transplantation CME/CNE/CPE Audio PodcastDr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD / Anthony R. Mato, MD, MSCE - Upgrading the Sequential Therapy Tool Kit for B-Cell Malignancies: New Evidence on the Individualized Use of BTK Inhibitors in Relapsed/Refractory CLL/SLL and MCLGo online to PeerView.com/DQM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up to the challenge of selecting and sequencing BTK inhibitor options in difficult B-cell cancer settings? This PeerView MasterClass and Case Forum activity recorded at the European hematology annual meeting explores BTK inhibitors as highly effective therapeutic tools for treating R/R CLL/SLL and MCL; join the experts and learn about important evidence on the “upgraded” sequential use of BTK inhibitors and other therapeutic innovations in pretreated B-cell cancer settings. Throughout, the experts will provide case...2022-08-101h 09PeerView Clinical Pharmacology CME/CNE/CPE VideoAnthony R. Mato, MD, MSCE - The Next Building Block for B-Cell Cancer Care: Exploring Personalized Treatment With Emerging BTK Inhibitor Options in CLL/SLL and MCLGo online to PeerView.com/QXD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Despite the success of BTK inhibitor therapy in B-cell malignancies, therapeutic resistance and intolerance represent barriers to effective, sustained anticancer therapy. What can clinicians do in the face of this challenge? In this case-based “Clinical Consults” discussion, a panel of leading experts meet this challenge head on and provide guidance on how to plan for and proactively capture the emergence of BTK resistance and intolerance, address the medical challenges of selecting effective sequential therapy, and prepare for the emer...2021-10-121h 02PeerView Oncology & Hematology CME/CNE/CPE Video PodcastAnthony R. Mato, MD, MSCE - The Next Building Block for B-Cell Cancer Care: Exploring Personalized Treatment With Emerging BTK Inhibitor Options in CLL/SLL and MCLGo online to PeerView.com/QXD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Despite the success of BTK inhibitor therapy in B-cell malignancies, therapeutic resistance and intolerance represent barriers to effective, sustained anticancer therapy. What can clinicians do in the face of this challenge? In this case-based “Clinical Consults” discussion, a panel of leading experts meet this challenge head on and provide guidance on how to plan for and proactively capture the emergence of BTK resistance and intolerance, address the medical challenges of selecting effective sequential therapy, and prepare for the emer...2021-10-121h 02PeerView Heart, Lung & Blood CME/CNE/CPE Video PodcastAnthony R. Mato, MD, MSCE - The Next Building Block for B-Cell Cancer Care: Exploring Personalized Treatment With Emerging BTK Inhibitor Options in CLL/SLL and MCLGo online to PeerView.com/QXD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Despite the success of BTK inhibitor therapy in B-cell malignancies, therapeutic resistance and intolerance represent barriers to effective, sustained anticancer therapy. What can clinicians do in the face of this challenge? In this case-based “Clinical Consults” discussion, a panel of leading experts meet this challenge head on and provide guidance on how to plan for and proactively capture the emergence of BTK resistance and intolerance, address the medical challenges of selecting effective sequential therapy, and prepare for the emer...2021-10-121h 02PeerView Internal Medicine CME/CNE/CPE Audio PodcastAnthony R. Mato, MD, MSCE - The Next Building Block for B-Cell Cancer Care: Exploring Personalized Treatment With Emerging BTK Inhibitor Options in CLL/SLL and MCLGo online to PeerView.com/QXD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Despite the success of BTK inhibitor therapy in B-cell malignancies, therapeutic resistance and intolerance represent barriers to effective, sustained anticancer therapy. What can clinicians do in the face of this challenge? In this case-based “Clinical Consults” discussion, a panel of leading experts meet this challenge head on and provide guidance on how to plan for and proactively capture the emergence of BTK resistance and intolerance, address the medical challenges of selecting effective sequential therapy, and prepare for the emer...2021-10-121h 02PeerView Heart, Lung & Blood CME/CNE/CPE Audio PodcastAnthony R. Mato, MD, MSCE - The Next Building Block for B-Cell Cancer Care: Exploring Personalized Treatment With Emerging BTK Inhibitor Options in CLL/SLL and MCLGo online to PeerView.com/QXD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Despite the success of BTK inhibitor therapy in B-cell malignancies, therapeutic resistance and intolerance represent barriers to effective, sustained anticancer therapy. What can clinicians do in the face of this challenge? In this case-based “Clinical Consults” discussion, a panel of leading experts meet this challenge head on and provide guidance on how to plan for and proactively capture the emergence of BTK resistance and intolerance, address the medical challenges of selecting effective sequential therapy, and prepare for the emer...2021-10-121h 02PeerView Oncology & Hematology CME/CNE/CPE Audio PodcastAnthony R. Mato, MD, MSCE - The Next Building Block for B-Cell Cancer Care: Exploring Personalized Treatment With Emerging BTK Inhibitor Options in CLL/SLL and MCLGo online to PeerView.com/QXD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Despite the success of BTK inhibitor therapy in B-cell malignancies, therapeutic resistance and intolerance represent barriers to effective, sustained anticancer therapy. What can clinicians do in the face of this challenge? In this case-based “Clinical Consults” discussion, a panel of leading experts meet this challenge head on and provide guidance on how to plan for and proactively capture the emergence of BTK resistance and intolerance, address the medical challenges of selecting effective sequential therapy, and prepare for the emer...2021-10-121h 02PeerView Clinical Pharmacology CME/CNE/CPE Audio PodcastAnthony R. Mato, MD, MSCE - The Next Building Block for B-Cell Cancer Care: Exploring Personalized Treatment With Emerging BTK Inhibitor Options in CLL/SLL and MCLGo online to PeerView.com/QXD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Despite the success of BTK inhibitor therapy in B-cell malignancies, therapeutic resistance and intolerance represent barriers to effective, sustained anticancer therapy. What can clinicians do in the face of this challenge? In this case-based “Clinical Consults” discussion, a panel of leading experts meet this challenge head on and provide guidance on how to plan for and proactively capture the emergence of BTK resistance and intolerance, address the medical challenges of selecting effective sequential therapy, and prepare for the emer...2021-10-121h 02PeerView Internal Medicine CME/CNE/CPE Video PodcastAnthony R. Mato, MD, MSCE - The Next Building Block for B-Cell Cancer Care: Exploring Personalized Treatment With Emerging BTK Inhibitor Options in CLL/SLL and MCLGo online to PeerView.com/QXD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Despite the success of BTK inhibitor therapy in B-cell malignancies, therapeutic resistance and intolerance represent barriers to effective, sustained anticancer therapy. What can clinicians do in the face of this challenge? In this case-based “Clinical Consults” discussion, a panel of leading experts meet this challenge head on and provide guidance on how to plan for and proactively capture the emergence of BTK resistance and intolerance, address the medical challenges of selecting effective sequential therapy, and prepare for the emer...2021-10-121h 02
Parlons des cancers du sangVivre avec un diagnostic de LNH selon la perspective de Jean-François RobertDans ce balado, Jean-François Robert nous parlera de son expérience avec le lymphome non-hodgkinien à cellules du manteau, diagnostic qu’il a reçu en 2002. Il abordera le diagnostic, les traitements, les effets secondaires et donnera des façons pratiques de les gérer ces différents effets.2020-10-0623 minParlons des cancers du sangVivre avec un diagnostic de Thrombocytémie essentielle selon la perspective d’Annie BertrandAnnie Bertrand est une jeune femme dans le domaine de l’enseignement et est la maman de trois garçons. Dans ce balado, elle nous parle de son expérience avec un diagnostic de thrombocytémie essentielle.2020-10-0222 minParlons des cancers du sangMyelofibrose: Conversation avec Dr Pierre VilleneuveDr Pierre Villeneuve est hématologue à l’Hôpital Général d’Ottawa, en charge de la clinique du myélofibrose. Dans ce balado, il nous parle de cette forme de cancer du sang: diagnostic, traitement, gestion des effets secondaires, recherche, etc.2020-09-2917 minParlons des cancers du sangRecevoir un diagnostic de LMA dans la vingtaine: l’histoire d’Alexandra YelleAlexandra Yelle habite St-Jérôme et a reçu un diagnostic de LMA a l’âge de 24 ans Dans ce balado, elle nous parle de comment elle a vécu le fait de recevoir un diagnostic de cancer dans la vingtaine.2020-09-2543 minParlons des cancers du sang10 faits sur la LMC par Marianne LemayMarianne Lemay a reçu un diagnostic de LMC à l’âge de 28 ans, qui a été détecté suite à une grossesse interrompue. Son fils avait 1 an et demi à l’époque. 1 an plus tard, elle a fondé sa propre entreprise qui vise à aider les organisations à prendre soin de leurs employés.2020-09-2232 minParlons des cancers du sangJouer un rôle actif dans la prise en charge de ses soins : l’histoire de Linda AugustMadame Linda August habite à Montréal et est une survivante d’un lymphome. Durant son expérience avec le cancer, Mme August a rapidement compris l’importance de prendre une part active dans le suivi de ses soins et de ses traitements. Elle nous parle de son expérience, donne des suggestions pour prendre une part active dans ses traitements et pour défendre ses droits et ses intérêts.2020-09-1822 minParlons des cancers du sangFaire face au deuilLucie Lessard habite la région de Québec et a perdu son conjoint en septembre 2017 d’un lymphome. Dans ce balado, elle nous livre ses suggestions et conseil pour faire face au deuil.2020-07-0610 minParlons des cancers du sangLeucémie lymphoïde chronique: point de vue d’un chercheurPascale Rousseau de la SLLC s’entretient avec le Dr Gilles Robichaud à propos de ses recherches sur la LLC dans cet épisode de « Parlons des cancers du sang ». Le Dr Robichaud est professeur et chercheur à l’Université de Moncton. Ses recherches sont financées par la SLLC. Il nous parle de ses travaux actuels et de la manière dont ils pourraient contribuer à un éventuel traitement contre la LLC.2020-07-0320 minParlons des cancers du sangVotre vie après le cancer - Histoires positives: Denis LemieuxDenis Lemieux est un père de famille âgé de 62 qui a reçu un diagnostic d’une LLC stade 1 soit sous observation. Il est quelqu’un de très sportif avec de bonnes habitudes de vie. Malgré que ce ne soit pas simple à tous les jours, il trouve important de prendre soin de lui, d’avoir de la gratitude et de conserver une attitude positive.
votrevieaprèslecancer.ca2020-05-2918 minParlons des cancers du sangVotre vie après le cancer - Cancer et finance: Comment réduire notre stress financierCarlo Monaco a reçu un diagnostic de lymphome de Hodgkin en 2002, à l’âge de 16 ans et a reçu deux transplantations de cellules souches en 2003. Il est dans le secteur des services financiers depuis 14 ans et est actuellement expert-conseils, Avantage collectif chez RBC.
Alec Garabedian détient un baccalauréat en commerce de l’Université McGill et est planificateur financier chez RBC depuis plus de 15 ans.
votrevieaprèslecancer.ca2020-05-2914 minParlons des cancers du sangVotre vie après le cancer - Donner du sens à sa vieVéronique Lefrançois est en rémission d’un lymphome hodgkinien depuis juillet 2017. Elle a écrit un livre sur son expérience avec le cancer qui s'intitule > Son expérience avec un cancer du sang l’a amené à voir la vie autrement.
votrevieapreslecancer.ca
2020-05-2819 minParlons des cancers du sangVotre vie après le cancer - Retour à l’écoleYasmine Kadri est une jeune survivante d’un lymphome de Hodgkin, diagnostiquée à l’âge de 17 ans. Après avoir complété un baccalauréat en sciences biomédicales, elle fait actuellement des études de médecine à l’Université de Montréal.
votrevieapreslecancer.ca2020-05-2823 minParlons des cancers du sangVotre vie après le cancer - Aider et soutenir les aidantsCatherine Anctil avait 25 ans quand son conjoint Tyler a été diagnostiqué avec un lymphome. Elle nous parle ici des émotions que cette expérience lui a fait vivre et de la façon dont elle l’a soutenu pendant et après les traitements.
votrevieapreslecancer.ca2020-05-2815 minParlons des cancers du sangVotre vie après le cancer - Aider la famille et les amis à faire face au cancerMelina Ladouceur est coach en matière de cancer à la Fondation du cancer de la région d’Ottawa.
votrevieapreslecancer.ca2020-05-2839 minParlons des cancers du sangVivre avec un diagnostic de LMA selon la perspective de Sylvie CamiréSylvie est en rémission de la leucémie myéloïde aiguë. Elle est infirmière à Québec. Elle est aussi engagée bénévolement par le comité mission de Québec.
sllcanada.org/podcasts2020-02-0627 minParlons des cancers du sangVivre avec un diagnostic de LLC selon la perspective de Raymond VlesRaymond habite à Montréal, et il est père de deux enfants adultes. Il vit avec un diagnostic de la leucémie lymphoïde chronique depuis 2010.
sllcanada.org/podcasts2020-02-0629 min
ASCO EducationRecent Approvals: Duvelisib for Adult Patients with Relapsed or Refractory CLL or SLLDr. Ian Flinn, Medical Oncologist specializing in hematologic malignancies at Tennessee Oncology, discusses the recent FDA approval of duvelisib for adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). If you enjoyed this podcast, make sure to subscribe for more weekly education content from ASCO University. We truly value your feedback and suggestions, so please take a minute to leave a review. If you are an oncology professional and interested in contributing to the ASCO University Weekly Podcast, email ascou@asco.org for more information. TRANSCRIPT (Intro Music Playing) As...2019-01-3004 min